DIA

This week, we were delighted to host the #DIAEurope2025 Programme Committee meeting at the DIA office in Basel, Switzerland. Our discussions were highly productive and we successfully continued the development of the sessions for each DIA Europe track. We are thrilled with the outcomes of this meeting and we would like to extend our heartfelt thanks to all Programme Committee members for their dedication and hard work in co-creating next year’s programme. We anticipate a conference rich in fruitful discussions, learning and networking opportunities that will meet the professional goals of all participants. If you would like to learn more about DIA Europe 2025, check out our website: https://bit.ly/45UYR3p. Save the date: 📅 18-20 March 2025 📍 Basel, Switzerland See you next year! Aimad Torqui Antonella Cardone Claudia Dollins Estelle Michael Gracy Crane Inka Heikkinen James Whitehead Kate Porch Kostas Papadakis Lada Leyens Magda Chlebus Mark Pellett Momir Radulović Monique Al Rebecca Lumsden Sabina Hoekstra-van den Bosch, PharmD FRAPS Sarah Pope Miksinski Susanne A. Tamara Di Carlantonio Thomas W. Møller Tim Powell Ursula Busse Willemijn van der Spuij Cláudia Ferreira Sara Torgal Vedran Raguž Nathalie Preiswerk Jean-Baptiste (JB) Cartier Ania Mitan #Conference #LifeSciences #Sustainability #Collaboration #Innovation

The DIA India Annual Meeting is back, and this year, it’s bigger than ever! We’re offering 3 specialised tracks focusing on: ◾ 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐢𝐜𝐞𝐬: Dive into development, clinical data, and regulatory challenges. ◾ 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐯𝐢𝐠𝐢𝐥𝐚𝐧𝐜𝐞: Explore vigilance and risk mitigation strategies. ◾ 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲: Discuss the impact of technology and AI on healthcare.   Connect with industry leaders, regulatory authorities, and other key stakeholders to influence the future of healthcare in India. Take advantage of early bird rates and secure your spot today: https://bit.ly/4bR5YM0. #DIAIndia #Pharmacovigilance #Clinical #RegulatoryAffairs #MedicalDevices

As part of our commitment to advancing patient-centered care, DIA is launching a #tolerability research project. This initiative aims to establish a standard definition of #patienttolerability in multiple solid and liquid tumor cancers, focusing on patient-reported outcomes that reflect real-world experiences and preferences. This study also aspires to develop guidelines on how to use this data to inform #clinicaltrial design, provider and patient decision-making, and more. Join us in this crucial effort to deepen our understanding of patient tolerability and ultimately improve patient outcomes worldwide. Learn more about the study’s objectives by emailing [email protected]. #Healthcare #LifeSciences

Are you interested in the evolving landscape of pharmacovigilance? Join our ‘Artificial Intelligence in Pharmacovigilance’ training course to learn about the latest technological advancements in this field. In this course, we will cover: ◾ How PV and its technologies are changing. ◾ Various AI technologies, including ChatGPT. ◾ Management perspectives and challenges, including people, skills, governance, audits, and compliance. ◾ Current PV IT platforms and their capabilities in AI and automation. ◾ Envisioning the ideal PV IT intelligence system of the future. Hear from the Course Director, Jan Petracek, why this training course is a must and register by 16 July to benefit from the early bird rate: https://bit.ly/45dtiRT. #Pharmacovigilance #DrugSafety #IT #ArtificialIntelligence #AI

At #DIA2024, a panel of experts, including Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research, expressed strong support for the accelerated approvals program. It has expedited drugs that fulfill unmet medical needs and provided patients with life-extending treatments for rare cancers. Joanne Eglovitch recaps the session via Regulatory Affairs Professionals Society (RAPS): https://lnkd.in/gkkD-AYw

Welcome to the July issue of Therapeutic Innovation & Regulatory Science (TIRS)! If you are DIA member, you have full access to both the articles below and the complete archive online. If not, please feel free to view the open-access articles.

Extending a heartfelt thank you to the San Diego Blood Bank and to all of the incredible #blooddonor heroes at #DIA2024! Together, we've made a difference and helped save lives. 𝐅𝐮𝐧 𝐅𝐚𝐜𝐭: A whopping 93% of event donors were first-timers! Your generosity and support will make a tremendous impact to those in need!

#DIA2024 united industry leaders, regulators, and patient advocates to discuss the future of #healthcare, and Tamei Elliott, DIA's Associate Director of Scientific Programs, and Radha Goolabsingh, DIA's Global Regulatory Strategy and Engagement Leader, briefly shared their biggest takeaways from the four-day event. Read more about what they learned and what they expect to happen as a result of the conversations that took place in San Diego.

Dr. Zili Li, DIA Fellow and former Chair of the China Regional Advisory Council, and David Mukanga, Deputy Director of Africa Regulatory Systems at the Bill & Melinda Gates Foundation, have joined DIA's Board of Directors. They will strengthen our commitment to advancing the #lifesciences worldwide by helping provide clarity, direction, and policy objectives. Learn more about the latest additions to the board: https://lnkd.in/gD3fSexV

As we gear up for #Canada24, we are excited to share a curated selection of recent publications highlighting collaborative developments within the Canadian #biopharma sector. 𝐀𝐫𝐭𝐢𝐜𝐥𝐞 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: Industry Perceptions and Experiences with the #AccessConsortium New Active Substance Work-Sharing Initiative (#NASWSI): Survey Results and Recommendations ➡️https://ow.ly/8Ifs50St2rj 𝐀𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: Using a survey developed by the #pharmaceutical industry trade associations of the five Access Consortium countries—Australia, Canada, Singapore, Switzerland, and the United Kingdom (UK)—this study gathered insights into the perceptions and experiences of the Access pathway held by affiliates of pharmaceutical companies.